MedTrace Logo

Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion

NCT01448018 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-08-13

No results posted yet for this study

Summary

The purpose of this study is to compare ranibizumab injection to hemodilution at the early phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both treatments may have a synergic effect.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

ranibizumab

3 monthly intravitreous injection as soon as possible after the inclusion

PROCEDURE

hemodilution

hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion

Sponsors & Collaborators

  • Centre Hospitalier Intercommunal Creteil

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448018 on ClinicalTrials.gov